6:01 PM
 | 
Jun 16, 2015
 |  BC Extra  |  Clinical News

Teva's Austedo meets in Phase III tardive dyskinesia study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said Austedo deutetrabenazine ( SD-809) met the primary endpoint in the Phase III ARM-TD trial to treat moderate to severe tardive dyskinesia.

Austedo led to an improvement of 3 points...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >